REPLACING: Antisoma's Preliminary Results for the Year Ended 30 June 2004
September 16, 2004 05:51 ET
|
Antisoma plc
LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004.
Announced today
* AS1404...
Antisoma's Preliminary Results for the Year Ended 30 June 2004
September 16, 2004 02:18 ET
|
Antisoma plc
LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004.
Announced today
* AS1404...
Antisoma plc reports Q3 results
May 13, 2004 02:01 ET
|
Antisoma plc
LONDON, May 13, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biotechnology company developing novel anti-cancer drugs, today announces its results for the three months ended 31 March 2004.
...
Antisoma plc Announces Findings Presented at AACR
March 29, 2004 01:02 ET
|
Antisoma plc
LONDON, UK, March 29, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, announces the presentation of promising new data from...
Antisoma plc -- R&D Update: AS1404 Advancing to Phase II Trials; AS1405 Starts Clinical Trials in Brain Cancer
March 22, 2004 02:02 ET
|
Antisoma plc
LONDON, March 22, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biopharmaceutical company specialising in the development of novel anti-cancer drugs, will today hold an R&D update for analysts...
Ursula Ney Joins Antisoma as Chief Operating Officer
February 25, 2004 02:05 ET
|
Antisoma plc
LONDON, Feb. 24, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the appointment of Dr Ursula Ney as Chief...
Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology
September 10, 2003 02:04 ET
|
Antisoma plc
LONDON, Sept. 10, 2003 (PRIMEZONE) -- Antisoma plc, (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has...
Antisoma Acquires Cytogen's Royalty Rights To R1549
September 09, 2003 02:08 ET
|
Antisoma plc
LONDON, and PRINCETON, N.J., Sept. 9, 2003 (PRIMEZONE) -- Antisoma plc (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation...
Antisoma plc -- Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market
August 26, 2003 02:05 ET
|
Antisoma plc
London, UK, August 26, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), the UK-based biopharmaceutical company, today announces that it has received approval for a...
Antisoma plc: Results Presented from AS1403 Phase I Biodistribution Study
August 22, 2003 02:02 ET
|
Antisoma plc
LONDON, Aug. 22, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be...